지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Fenofibrate is one of PPAR-α (peroxisome proliferator activated receptor alpha) agonists. Fenofibrate decreases effectively triglycerideand increases high density lipoprotein cholesterol level through the effect on lipoprotein lipase, hepatic production anddegradation of lipoproteins. Fenofibrate was recommended as the drug for hypertriglyceridemia treatment in European guideline releasedin 2011. But American heart association guideline in 2013 did not recommend non-statin therapy including fibrate for theprevention of atherosclerotic cardiovascular disease. But fenofibrate is still considered as the important drug for the management ofatherogenic dyslipidemia especially in patients with metabolic syndrome and diabetes to reduce the residual risk after statin therapyfrom the evidence of many studies. Fibrates including bezafibrate, gemfibrozil, and fenofibrate increased serum creatinine level inseveral studies. But the mechanism of change in renal function is not clear till now. And the reversibility of renal function with drugdiscontinuation is dependent on the kinds of fibrate. Fenofibrate increased serum creatinine level, decreased albuminuria and renalfunction was reversible with the drug discontinuation in large clinical trials. In these days renal function change with fenofibratetherapy in Korean patients with hypertriglyceridemia was investigated. Fenofibrate treatment for 2 months increased serum creatininelevel significantly and old age was associated with the change of renal function in multivariate analysis. Short-term therapysignificantly increased serum creatinine level even within normal range, and this change may be important in some groups especiallyold age.
목차
등록된 정보가 없습니다.
참고문헌 (10)
참고문헌 신청
ACCORD Study Group / 2010 / Effects of combination lipid therapy in type 2 diabetes mellitus / N Engl J Med 362 : 1563 ~ 1574
Cho JH / 2013 / Effect of Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertension and Hypertriglyceridemia / J Lipid Atheroscler 2 : 19 ~ 26
Davis TM / 2011 / Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Stud
Davis TM / 2011 / Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mell
ESC/EAS Guidelines for the management of dyslipidaemias / 2011 / The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the Europ
Cho JH / 2013 / Effect of Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertension and Hypertriglyceridemia / J Lipid Atheroscler 2 : 19 ~ 26
Davis TM / 2011 / Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Stud
Davis TM / 2011 / Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mell
ESC/EAS Guidelines for the management of dyslipidaemias / 2011 / The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the Europ
이 논문의 저자 정보
최근 본 자료
댓글(0)
0